The enhanced glucose clearance from the circulation following intraperitoneal injection of glucose (Fig. 4D) or insulin (Fig. 4E) further corroborates our assumption that intestinal Ces2c overexpression protects from HFD‐induced insulin resistance. The gene discussed is INS; the disease is Insulin resistance.